Evidence map›Paper›PMID 38746691›Full record

ArticleNature. Mental health2024

A systematic review of pharmacogenetic testing to guide antipsychotic treatment.

Noushin Saadullah Khani, Georgie Hudson, Georgina Mills, Soumita Ramesh, Lauren Varney, Marius Cotic, Rosemary Abidoph, Alvin Richards-Belle, Lorena Carrascal-Laso, Manuel Franco-Martin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature. Mental health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Effect ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Noushin Saadullah KhaniMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.ORCID 0009-0004-6678-4693
Georgie HudsonMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.ORCID 0000-0002-5002-4890
Georgina MillsMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Soumita RameshMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Lauren VarneyMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Marius CoticMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Rosemary AbidophMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.
Alvin Richards-BelleMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.ORCID 0000-0001-8577-9380
Lorena Carrascal-LasoServicio de Psiquiatría, Hospital Provincial de Zamora, Instituto de Investigación Biomédica de Salamanca, Zamora, Spain.
Manuel Franco-MartinServicio de Psiquiatría, Hospital Provincial de Zamora, Instituto de Investigación Biomédica de Salamanca, Zamora, Spain.ORCID 0000-0002-3639-2523
Benjamin Skov Kaas-HansenDepartment of Intensive Care (4131), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-1023-0371
Gesche JürgensClinical Pharmacological Unit, Zealand University Hospital, Roskilde, Denmark.
Barbara BarrettDepartment of Health Services and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Huajie JinKing's Health Economics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0002-3872-3998
Elvira BramonMental Health Neuroscience Research Department, Division of Psychiatry, University College London, London, UK.

Funding

Medical Research Council G0901310Medical Research Council G1100583Medical Research Council MR/W020238/1Wellcome Trust
6 · The paper itself

Abstract

Pharmacogenomics could optimize antipsychotic treatment by preventing adverse drug reactions, improving treatment efficacy or relieving the cost burden on the healthcare system. Here we conducted a systematic review to investigate whether pharmacogenetic testing in individuals undergoing antipsychotic treatment influences clinical or economic outcomes. On 12 January 2024, we searched MEDLINE, EMBASE, PsycINFO and Cochrane Centrale Register of Controlled Trials. The results were summarized using a narrative approach and summary tables. In total, 13 studies were eligible for inclusion in the systematic review. The current evidence base is either in favor of pharmacogenetics-guided prescribing or showed no difference between pharmacogenetics and treatment as usual for clinical and economic outcomes. In the future, we require randomized controlled trials with sufficient sample sizes that provide recommendations for patients who take antipsychotics based on a broad, multigene panel, with consistent and comparable clinical outcomes.

Indexed as

Genetics researchPharmacogenetics

Identifiers

PMID38746691
PMCPMC11088993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.